ProPhase Labs, Inc. (PRPH) shares ended the last trading session 8.5% higher at $8.42. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session.

Ted Karkus, ProPhase Lab’s Chief Executive Officer, commented, “Q2 2024 was a transformative quarter for ProPhase. Our teams across all subsidiaries have made remarkable progress, particularly in ...

ProPhase Labs, Inc. (US74345W1080) remains a small-cap Nasdaq healthcare stock whose latest reported operating figures and ...

ProPhase Labs Inc. (Nasdaq: PRPH) (“ProPhase”) is a next-generation biotech, genomics and diagnostics company. Our goal is to create a healthier world with bold action and the power of insight. We’re ...

Ted Karkus, Chairman & CEO, opened by emphasizing the critical importance of shareholder voting on the company's proxy, noting, "If you do not vote for our proxy, you are putting our company in harm's ...

Financing provides bridge to multiple potentially significant liquidity events and crypto strategies UNIONDALE, NY, July 23, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), (the "Company" ...

ProPhase Labs (PRPH) has initiated a potential sale or strategic partnership process for BE-Smart, its clinically validated esophageal cancer risk stratification test. As part of this process, ...

Transaction Eliminates More Than $20 Million in Debt, and Other Financial Obligations, Provides $2 million in Cash and Significantly Enhances the Company's Balance Sheet and Liquidity The Company will ...

ProPhase Labs has put a diagnostic-testing unit into bankruptcy, a move it has been planning as a way to collect on millions of dollars in accounts receivables from its days processing Covid-19 tests ...